✓ Medically reviewed by  ·  Last reviewed: May 2026

Morgan Ellis

Pharmacy Researcher · 8 years experience

Pharmacy researcher with 8 years reviewing clinical drug information, generic formulation equivalence, and international pharmaceutical standards. Focuses on patient-facing accuracy in medication education.

Of every molecule inside a human cell, few do more heavy lifting than nicotinamide adenine dinucleotide — better known as NAD⁺. It powers the enzymes that turn food into ATP, licenses sirtuins to silence the wrong genes at the wrong time, and keeps the PARP repair crew armed against the daily drumbeat of DNA damage. When NAD⁺ levels are abundant, cells behave young. When they fall, the whole metabolism starts to feel its age.

And fall they do. Plasma NAD⁺ drops roughly 60 percent between early adulthood and later life, with parallel declines in skin, liver, and skeletal muscle tissue. That slow leak is now one of the most reproducible biochemical hallmarks of ageing, and it is why “boosting NAD⁺” has become shorthand for one of the most active areas of longevity research in the world.

This guide is the deep dive on what NAD⁺ actually is, how it works inside a cell, what the research genuinely shows, what subcutaneous injection protocols look like, and how it compares to oral precursors like NR and NMN. It is written for researchers, biohackers, and curious patients who want the honest version — not the supplement-ad version.

NAD⁺: Benefits, Dosage, Side Effects & The Honest Science (2026)

Last updated: April 17, 2026 · Reviewed by a licensed pharmacist (MedsBase Medical Team)

What Is NAD⁺? (Definition & Background)

NAD⁺ stands for nicotinamide adenine dinucleotide, a coenzyme present in every living cell on Earth. It is built from two nucleotides — one containing adenine, the other containing nicotinamide — joined through their phosphate groups. Despite the “peptide” shorthand used casually in research catalogs, NAD⁺ is not a peptide; it is a small-molecule cofactor that chemical biology has studied continuously since it was first isolated by Harden and Young in 1906.

The “plus” in NAD⁺ denotes the oxidised form of the molecule. In its reduced form, NADH, it carries two extra electrons picked up during glucose and fatty-acid oxidation and delivers them to the mitochondrial electron transport chain, where those electrons drive the synthesis of ATP — the actual unit of cellular currency. Roughly every molecule of ATP your body makes today passed through an NAD⁺/NADH redox cycle on its way there.

That alone would make NAD⁺ important. What made it fashionable, however, was the discovery that a second class of enzymes — the sirtuins — use NAD⁺ as a fuel to deacetylate histones, transcription factors, and metabolic proteins. Sirtuin activity shapes how long cells live, how efficiently they repair damage, and how gracefully tissues age. Without NAD⁺, sirtuins simply cannot work. And as NAD⁺ falls with age, sirtuin activity falls with it.

A third consumer, the PARP (poly-ADP-ribose polymerase) family, uses NAD⁺ to flag and repair DNA single-strand breaks. A fourth, CD38, degrades NAD⁺ as part of immune-cell signalling and becomes chronically overactive in old tissue, which is one major reason NAD⁺ levels slide. These three consumers — sirtuins, PARPs, and CD38 — together explain why ageing burns NAD⁺ faster than the body can make it.

How Does NAD⁺ Work? (Mechanism & Science)

NAD⁺ acts through two parallel mechanisms that run in every cell simultaneously.

1. The Redox Role — Powering the Mitochondria

In glycolysis, the citric acid cycle, and fatty-acid oxidation, NAD⁺ accepts electrons from metabolic substrates and becomes NADH. NADH then delivers those electrons to Complex I of the electron transport chain. The resulting proton gradient powers ATP synthase — the rotary nanomachine that builds roughly one ATP molecule per 2.5 protons translocated. Without adequate NAD⁺, the whole cycle stalls and ATP output collapses. This is why NAD⁺ depletion is particularly punishing for the most energy-hungry organs — brain, heart, and skeletal muscle.

2. The Signalling Role — Sirtuins, PARPs, and CD38

The signalling pathway is more subtle but arguably more important for longevity. Sirtuins, PARPs, and CD38 are all NAD⁺-consuming enzymes: they physically cleave NAD⁺ to perform their jobs. That means each enzyme’s activity is directly limited by intracellular NAD⁺ availability.

SIRT1 and SIRT3, the best-studied sirtuins, regulate mitochondrial biogenesis, oxidative-stress responses, and the expression of genes involved in metabolic efficiency. When NAD⁺ is plentiful, sirtuins fire often, mitochondria stay clean and numerous, and cells behave metabolically young. When NAD⁺ is scarce, sirtuins go quiet, mitochondrial turnover slows, and the cell accumulates damage it would otherwise repair.

PARP1 and PARP2 rush to every DNA strand break and use NAD⁺ to build a signalling polymer called PAR, which recruits the rest of the repair machinery. In tissues exposed to chronic damage — skin from UV, liver from oxidative stress, neurons from ischaemia — PARPs can consume staggering amounts of NAD⁺, leaving sirtuins starved. Raising systemic NAD⁺ is one of the few interventions that addresses both the repair and signalling ends of this equation at once.

3. The Salvage Pathway — Where Supplemental NAD⁺ Lands

Cells do not absorb intact NAD⁺ efficiently across the plasma membrane. Instead, injected or infused NAD⁺ is broken down extracellularly into nicotinamide and other precursors, which are taken up and resynthesised into fresh NAD⁺ through the NAMPT salvage pathway. NAMPT is the rate-limiting enzyme in that recycling loop, and it generates an estimated 85 percent of the body’s total NAD⁺. This biochemistry is the reason both direct NAD⁺ and oral precursors like NR and NMN ultimately raise the same intracellular pool — the precursors just take a faster or slower route to get there.

Key Uses & Applications

NAD⁺ supplementation, whether by injection or via oral precursors, is being studied and used in five main areas.

Longevity & Healthspan

This is the most heavily promoted use and also the one with the thinnest clinical evidence. The logic is straightforward: NAD⁺ falls with age, restoring it engages sirtuins, sirtuins extend healthspan in most model organisms tested, therefore restoring NAD⁺ should slow at least some aspects of ageing in humans. The biochemistry is solid. The human outcomes data is early but genuinely encouraging — see the research section below.

Metabolic Health

Several trials have tested NAD⁺ precursors in people with insulin resistance, prediabetes, and fatty liver disease. Results are mixed but frequently positive on surrogate endpoints — improved insulin sensitivity, lower liver fat, and modest decreases in fasting glucose. The effect sizes are smaller than a good GLP-1 agonist but the safety profile is far cleaner.

Neurological Support

Brain tissue is NAD⁺-hungry and among the hardest hit by age-related decline. Active 2025 trials are testing NAD⁺ precursors in Alzheimer’s, Parkinson’s, and mild cognitive impairment. A recent 8-week randomised trial of 1 g/day nicotinamide riboside in older adults with subjective cognitive decline showed favourable changes in plasma Alzheimer’s biomarkers — preliminary, but one of the strongest signals in the whole field.

Athletic Recovery & Performance

This is where injectable NAD⁺ has found its largest following. The theory is that sustained NAD⁺ in working muscle supports mitochondrial turnover, reduces oxidative damage, and accelerates recovery between sessions. Human data here is mostly anecdotal — rigorously controlled athletic trials are still limited — but the mechanistic case is strong enough that it has become popular in strength-and-conditioning circles alongside creatine and electrolytes.

Addiction Recovery

NAD⁺ infusion clinics have built an entire sub-industry around treating opioid, alcohol, and stimulant withdrawal. Reported outcomes include reduced cravings, improved sleep, and blunted withdrawal symptoms. Published data remains limited and most protocols are anecdotal, but the underlying biochemistry — NAD⁺ restoring energy metabolism in neurons stressed by chronic substance use — is plausible.

Safety Profile, Side Effects & Dosage

NAD⁺ is one of the more benign compounds in the injectable longevity space. Because it is a naturally occurring coenzyme, the body has robust mechanisms for handling excess. Most reported side effects are short-lived and dose-related.

Common Side Effects

• Flushing and warmth — the most common reaction, usually in the first 5–15 minutes after injection or infusion. Caused by rapid peripheral vasodilation. Lessens with slower dosing and smaller boluses.
• Nausea and brief chest tightness — reported mostly during fast intravenous infusion. Uncommon with subcutaneous dosing at physiological amounts.
• Injection-site tenderness — mild redness or swelling lasting a few hours, typical of any subcutaneous protein-free compound.
• Transient elevation in heart rate — usually resolves within an hour, again linked to infusion speed.

Dosage Reference Ranges

Dosing depends heavily on the route. These figures are observational from clinical and compounding protocols, not personal recommendations.

• Subcutaneous (SC): 50–200 mg per injection, 2–5 times per week. Start at 25–50 mg and titrate upward by ~25 mg weekly as tolerated.
• Intramuscular (IM): similar range to SC, with possibly faster uptake. Rotate injection sites to avoid muscle soreness.
• Intravenous (IV): used clinically at 250–1000 mg per session, infused over 2–4 hours. Faster infusion sharply increases flushing and chest-tightness incidence.
• Cycle length: most protocols run for 4–12 weeks on, followed by a maintenance phase of 1–2 doses per week or a switch to oral precursors.

Contraindications

NAD⁺ has no absolute contraindications in otherwise healthy adults, but several groups should avoid it or use it only under close medical supervision: anyone with active cancer (because sirtuin and PARP activity modulation is complex in malignancy), pregnant or breastfeeding individuals (insufficient safety data), and people with severe kidney or liver disease (clearance is reduced and the risk–benefit math changes). Anyone on PARP-inhibitor cancer therapy should particularly avoid NAD⁺ precursors, which may interfere directly with the drug’s mechanism.

What Does the Research Say?

Age-Related NAD⁺ Decline — Well Established

Multiple independent research groups have measured an approximately 60 percent decline in plasma and tissue NAD⁺ between young adulthood and later decades. The drop is particularly steep in skin, skeletal muscle, and brain tissue, and it correlates with measurable declines in mitochondrial function, insulin sensitivity, and DNA repair capacity. This finding is one of the most reproducible observations in the ageing biology literature.

Precursor Trials — Positive on Surrogate Markers

Published randomised controlled trials of oral nicotinamide riboside and nicotinamide mononucleotide have consistently shown the expected biochemistry: blood NAD⁺ rises by 30–150 percent depending on dose and formulation. Clinical endpoints are harder. Cognitive, cardiovascular, and metabolic outcomes vary from trial to trial, but the trend across studies is mildly favourable with no major safety signals.

A 2025 crossover trial tested 350 mg of liposomal NMN in healthy men over 40 and found it raised NAD⁺ significantly more than non-liposomal NMN — confirming that formulation matters substantially and that earlier negative trials may have used formulations with poor bioavailability.

Injectable NAD⁺ — Less Published, More Anecdotal

There are far fewer peer-reviewed trials of injectable NAD⁺ than of oral precursors, largely because NAD⁺ has always been regulated as a research chemical rather than a drug. Functional-medicine clinics have published case series and uncontrolled open-label studies showing improvements in energy, cognition, and mood, but high-quality blinded trials are still scarce. The mechanistic case is strong; the clinical trial infrastructure simply has not caught up.

Rare-Disease and Neurodegeneration — Emerging Signal

2024–2025 saw several small trials in rare diseases with premature ageing features (Werner syndrome, Cockayne syndrome) and neurodegenerative conditions (Parkinson’s, Alzheimer’s) test NAD⁺ supplementation. Results are preliminary but consistent: NAD⁺ precursors are well tolerated and show encouraging effects on biomarkers of mitochondrial function and DNA damage. These indications are where formal regulatory approval is most likely to land first.

NAD⁺ vs NR vs NMN vs Oral Precursors

Understanding the differences between direct NAD⁺ and its oral precursors is essential to choosing a sensible protocol.

Practical takeaway. Direct NAD⁺ is best used for acute restoration or investigational protocols where rapid systemic elevation matters. Oral precursors — especially well-formulated NMN or NR — are more convenient, cheaper, and better suited to long-term maintenance. Many practitioners combine the two: a 4–8 week injection loading phase, followed by oral maintenance.

How to Use NAD⁺ (Reconstitution, Storage, Injection Technique)

Research-grade NAD⁺ typically ships as a lyophilised (freeze-dried) powder in 100, 500, or 1000 mg vials. It must be reconstituted with bacteriostatic water for injection before use. Sterile saline is an acceptable substitute but has a shorter post-reconstitution shelf life. Avoid tap or distilled water.

Reconstitution

For a 500 mg vial, adding 5 mL of bacteriostatic water gives a concentration of 100 mg/mL — a common working solution. Inject the water slowly down the inside wall of the vial to avoid foaming the powder. Gently swirl (do not shake) until fully dissolved. The solution should be clear to very slightly yellow; a dark-yellow, cloudy, or particulate solution indicates degradation and should be discarded.

Storage

Reconstituted NAD⁺ is stable refrigerated (2–8 °C) for approximately 14 days if made with bacteriostatic water, or 5–7 days with plain saline. Unreconstituted vials are stable for many months in a freezer. Protect from light; NAD⁺ is photosensitive.

Subcutaneous Injection Technique

• Draw the required dose into a 0.3–1 mL insulin syringe (29–31 gauge, 8–13 mm needle).
• Choose an injection site with loose subcutaneous tissue: abdominal area 2 inches from the navel, upper outer thigh, or back of the upper arm.
• Clean with an alcohol swab and let it dry.
• Pinch the skin, insert the needle at 45–90°, aspirate briefly, then push the plunger slowly (over 5–10 seconds) to minimise the flush reaction.
• Rotate sites between injections to prevent lipohypertrophy.

Slower pushes reduce flushing and chest tightness dramatically. If you feel a wave of warmth or anxiety, stop, breathe, and the sensation typically passes in a few minutes.

Frequently Asked Questions

What is NAD⁺ used for?

NAD⁺ is a coenzyme every cell needs to convert food into ATP, repair DNA through PARPs, and regulate gene expression through sirtuins. Supplemental NAD⁺ is used to counter the age-related decline in tissue NAD⁺ levels, which research has linked to declining energy metabolism, mitochondrial health, and DNA repair capacity. It is also used in longevity protocols, metabolic-health interventions, athletic recovery stacks, and emerging neurodegeneration research.

Is NAD⁺ a peptide?

No. NAD⁺ is a coenzyme built from two nucleotides — nicotinamide and adenine — joined through their phosphate groups. It contains no peptide bonds. The MedsBase peptide catalog lists NAD⁺ alongside peptides because the longevity research community uses them in the same protocols, not because the molecule is chemically a peptide.

How quickly does injected NAD⁺ work?

Blood NAD⁺ levels rise within minutes of injection. Subjective effects — energy, mental clarity, mood — are typically reported within the first 1–3 days of regular dosing. Deeper changes in mitochondrial function and cellular resilience build over 4–8 weeks. Practitioners generally tell patients not to judge a protocol until they have completed at least one full cycle.

Is NAD⁺ injection safer than IV infusion?

For most users, yes. IV infusion delivers a large bolus quickly, which drives the flushing, nausea, and chest-tightness reactions most people want to avoid. Subcutaneous injection delivers a smaller dose over a longer absorption window and dramatically reduces those reactions. IV is still appropriate for acute restoration or certain research protocols, but SC is the daily-driver route for the majority of users.

How much NAD⁺ should I inject?

Clinical and compounding protocols generally start at 25–50 mg subcutaneous and titrate up by about 25 mg per week as tolerated, with typical maintenance doses in the 50–200 mg range, administered 2–5 times per week. These figures are clinical observations, not personal advice — actual dosing should be set by a qualified physician who understands your goals and medical history.

Can NAD⁺ help with weight loss?

Indirectly. Higher NAD⁺ levels support mitochondrial biogenesis, improve insulin sensitivity, and increase metabolic efficiency. In trials, changes in body composition are modest unless combined with diet and exercise. NAD⁺ is not a weight-loss drug and should not be compared to retatrutide or other GLP-1 agonists for that purpose — different mechanisms, different expectations.

Does NAD⁺ suppress the body’s own NAD⁺ production?

No. The NAMPT salvage pathway is not downregulated by exogenous NAD⁺ in any meaningful way. When you stop injecting, your native synthesis continues unchanged. This is one of the advantages of NAD⁺ over hormone-like compounds, where shutdown and rebound are real risks.

Can I stack NAD⁺ with other peptides?

Yes, and it is commonly done. NAD⁺ supports the mitochondrial energy and DNA-repair pathways that most other peptide interventions rely on. Frequent stack partners include BPC-157 and TB-500 for recovery, ipamorelin + CJC-1295 for growth-hormone pulsatility, and oral NR or NMN for sustained maintenance between injection cycles. Stacking should be discussed with a physician familiar with peptide pharmacology.

How long should a NAD⁺ cycle last?

Most functional-medicine protocols run a loading phase of 4–8 weeks at 2–5 doses per week, followed by a maintenance phase of 1–2 doses per week, or a switch to oral precursors for ongoing support. Some practitioners run longer continuous cycles of 12 weeks before tapering. There is no clear evidence that indefinite use damages any organ system, but planned breaks allow reassessment and prevent psychological over-reliance on the tool.

The Bottom Line — Is NAD⁺ Worth It?

NAD⁺ sits at the crossroads of every major ageing pathway — mitochondrial energy, DNA repair, sirtuin signalling, and metabolic regulation. The basic science case for restoring NAD⁺ in mid-life is as strong as any single intervention in the longevity space. The clinical outcomes picture is less mature: precursor trials are broadly encouraging but not definitive, and injectable NAD⁺ still lacks the large blinded trials that would elevate it from “promising” to “proven.”

For adults 35 and up who care about mitochondrial health and metabolic efficiency — and who are willing to invest in a compound with strong mechanism and evolving clinical evidence — NAD⁺ earns a legitimate seat at the table. The safety profile is clean, the biochemistry is deep, and the downside of trying it under reasonable medical supervision is small.

A sensible entry strategy is a 4–8 week subcutaneous loading phase at moderate doses, a checkpoint of subjective energy and objective biomarkers (HRV, fasting glucose, resting heart rate), and then a decision to continue, taper to maintenance, or switch to oral precursors. To understand where NAD⁺ fits in the wider cellular-recovery landscape, see our best peptides for muscle recovery overview, and for the growth-hormone side of the longevity equation, our sermorelin peptide guide and tesamorelin peptide guide are the natural next reads.

When you are ready to source high-purity material, verified NAD⁺ at MedsBase ships with full documentation and pharmaceutical-grade purity across 100 mg, 500 mg, and 1000 mg vial sizes. Used under proper supervision, it remains one of the most mechanistically defensible compounds in the entire longevity toolkit.

Related Guides

Written by

Sophie Chen

Pharmaceutical Content Researcher · 8 years experience

Sophie Chen is a pharmaceutical content researcher with 8 years covering generic medication access and clinical pharmacology. She specialises in international regulatory frameworks, bioequivalence standards, and patient-facing education on therapeutic drug classes. She is not a clinician.